QUERCIS PHARMA
Quercis Pharma is a biopharmaceutical company that brings innovative and safe medicine to patients with orphan diseases. It is advancing a development pipeline of late-stage clinical studies that focus on the prevention of VTE in cancer patients. In addition, Quercis targets other diseases associated with thrombotic events, such as sickle cell disease (SCD), Ebola, and COVID-19. The Company’s lead drug candidate acts as an antithrombotic with a significantly lower risk of adverse events than existing treatments. The company was founded in 2019 and is based in Zug, Switzerland.
QUERCIS PHARMA
Industry:
Biopharma Biotechnology Life Science Medical Pharmaceutical
Founded:
2019-01-01
Address:
Zug, Zug, Switzerland
Country:
Switzerland
Website Url:
http://www.quercis.com
Total Employee:
11+
Status:
Active
Total Funding:
150 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Domain Not Resolving Apache
Similar Organizations
Antengene Corporation
Antengene is a developer of biotechnology and bio-pharmaceuticals intended to provide medicine treatment for tumor.
Arrakis Therapeutics
Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.
Mikrobiomik
Mikrobiomik is a biopharmaceutical company that provides innovative solutions for chronic diseases.
Numab
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.
Oxford Cannabinoid Technologies
OCT is a biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Stefan Wohlfeil Chief Medical Officer @ Quercis Pharma
Chief Medical Officer
2020-03-01
Thomas Lines Founder, CEO and Director @ Quercis Pharma
Founder, CEO and Director
Investors List
The Global Emerging Markets Group
The Global Emerging Markets Group investment in Private Equity Round - Quercis Pharma
Official Site Inspections
http://www.quercis.com Semrush global rank: 9.09 M Semrush visits lastest month: 217
- Host name: 212.243.197.113
- IP address: 212.243.197.113
- Location: Onex Switzerland
- Latitude: 46.1877
- Longitude: 6.0981
- Timezone: Europe/Zurich
- Postal: 1213
More informations about "Quercis Pharma"
Quercis Pharma – FOR A HEALTHIER WORLD
Quercis Pharma AG is a privately owned, biopharmaceutical company based in Zug, Switzerland. Quercis Pharma is advancing a development pipeline of late-stage clinical studies that focus on the prevention of VTE in cancer patients …See details»
Quercis Pharma - Crunchbase Company Profile & Funding
Quercis Pharma is a biopharmaceutical company that brings innovative and safe medicine to patients with orphan diseases. It is advancing a development pipeline of late-stage clinical …See details»
Quercis Pharma AG – Swiss Biotech
Quercis Pharma AG is a private Swiss biotech company advancing a novel antithrombotic in multiple indications: the lead program is prevention of Venous Thrombosis Embolism in advanced cancer patients (phase III) followed by …See details»
Mission – Quercis Pharma
Quercis is studying the use of its novel, proprietary and orally available anti-thrombotic, anti-cancer, antiviral and immuno-modulatory platforms to deliver innovative, effective, safe and broadly accessible treatments to patients with …See details»
Quercis Pharma Driving a Paradigm Shift Anticoagulation with an …
Quercis Pharma's pipeline developments include the relationship between viral illness and thrombosis. The potential influence of PDI in this context sparks hope for future advancements …See details»
Quercis Pharma - LinkedIn
For a Healthier World | Quercis Pharma AG is leveraging its novel antithrombotic platform to deliver safe and innovative treatments to patients with a variety of complex diseases that are poorly...See details»
Quercis Pharma AG - Life-Sciences-Europe.com
Jan 1, 2019 · Quercis Pharma AG is a private, biopharmaceutical company based in Zug, Switzerland. Quercis Pharma is advancing a development pipeline of late-stage clinical studies …See details»
Pioneering Cancer Associated Thrombosis Prevention
Quercis Pharma is a clinical-stage biotechnology company with three Phase III-ready assets under development. These assets demonstrate significant potential, with market opportunities for each of them estimated in the billions of dollars.See details»
Quercis Pharma Appoints Philippe Douste-Blazy, M.D. to Board of …
Nov 12, 2020 · As chairman of UNITAID, an international organization that supports innovations to prevent, diagnose and treat serious viral diseases more quickly, affordably and effectively, …See details»
Quercis Pharma: Revolutionizing Anticoagulation in …
In 2019, Quercis Pharma strategically acquired Clinical Stage Assets, heralding its entry into the biopharmaceutical domain. Guided by CEO Thomas Lines, the company pioneers a proprietary platform encompassing anti-thrombotic, anti …See details»
QUERCIS PHARMA LICENSES KEY PATENTS FOR …
Jan 21, 2021 · Quercis Pharma AG is a private, biopharmaceutical company based in Zug, Switzerland. Quercis Pharma is advancing a development pipeline of late-stage clinical studies …See details»
Quercis Pharma | Top Drug Discovery and Development Solutions …
Quercis Pharma stands as a distinctive company boasting some of the world’s most exceptional Cancer and thrombosis specialists. For instance, Dr. Jean-Pierre Bizzari, the Chairman of its …See details»
Quercis Announces Executive Leadership Appointments - PR …
ZUG, Switzerland, April 13, 2021 /PRNewswire/ -- Quercis Pharma AG, a private, clinical stage biopharmaceutical company leveraging its novel antithrombotic platform, today announces the...See details»
Quercis Pharma Secures USD 150 Million Investment Commitment …
Dec 9, 2021 · Quercis is currently advancing its lead clinical candidate, Isoquercetin, designed to prevent thromboembolic events in metastatic pancreatic cancer patients, under a Special …See details»
University and Quercis Pharma Sign Exclusive Worldwide License …
May 20, 2021 · Quercis Pharma AG, a private, clinical stage biopharmaceutical company, has signed a worldwide license agreement with Western New England University (WNE) of …See details»
Quercis Pharma Secures $150M Investment Commitment from GEM
Quercis Pharma AG, a private, clinical stage biopharmaceutical company leveraging its novel antithrombotic platform, today announced that it has signed an Agreement with GEM Global …See details»
Quercis Announces Executive Leadership Appointments
New executives to the Company’s leadership team. John Boghossian, former Vice President of Operations at COMPASS Pathways, will join Quercis as Chief Executive Officer; Manon …See details»
Isoquercetin - Quercis Pharma - AdisInsight - Springer
Oct 25, 2023 · If your organization or you do not have a subscription, try one of the following: Contacting your organization’s admin about adding this content to your AdisInsight …See details»
Quercis Pharma Licenses Key Patents for Thromboembolism …
ZUG, Switzerland, Jan. 25, 2021 /PRNewswire/ -- Quercis Pharma AG, a private, clinical stage biopharmaceutical company leveraging its novel antithrombotic platform, announced that it has …See details»
Targeting the - Oxford Academic
Nov 2, 2024 · An adenine base editing approach was developed to efficiently and specifically correct the IDH1 R132H mutation in different IDH1-mutant glioma models.. The correction of …See details»